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Summary
We describe a group of small-molecule inhibitors of
Jun kinase (JNK)-dependent apoptosis. AEG3482,
the parental compound, was identified in a screening
effort designed to detect compounds that reduce apo-
ptosis of neonatal sympathetic neurons after NGF
withdrawal. We show that AEG3482 blocks apoptosis
induced by the p75 neurotrophin receptor (p75NTR)
or its cytosolic interactor, NRAGE, and demonstrate
that AEG3482 blocks proapoptotic JNK activity. We
show that AEG3482 induces production of heat shock
protein 70 (HSP70), an endogenous inhibitor of JNK,
and establish that HSP70 accumulation is required
for the AEG3482-induced JNK blockade. We show
that AEG3482 binds HSP90 and induces HSF1-depen-
dent HSP70 mRNA expression and find that AEG3482
facilitates HSP70 production while retaining HSP90
chaperone activity. These studies establish that
AEG3482 inhibits JNK activation and apoptosis by
a mechanism involving induced expression of HSP
proteins.
Introduction
Multicellular organisms eliminate superfluous cells during
development through the process of apoptosis. Most
forms ofapoptosis converge oncaspasesasdownstream
effectors, and a significant body of work indicates that
caspases are activated by one of two main pathways.
The intrinsic pathway involves induced permeabilization
of the outer mitochondrial membrane, leading to the re-
lease of several proapoptotic factors, including cyto-
chrome C and SMAC, that cooperate to facilitate ac-
tivation of initiator caspase-9, which, in turn, leads to
activation of effector caspases such as caspase-3. The
extrinsic pathway is initiated by ligand binding to cell sur-
face death receptors, and this binding induces the assem-
bly of a death-inducing signaling complex that facilitates
activation of initiator caspase-8. There is extensive cross-
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3 These authors contributed equally to this work.talk between these pathways, and activation of the extrin-
sic apoptotic pathway often leads to induction of the in-
trinsic pathway (reviewed in [1]).
Activation of Jun kinase (JNK) has emerged as a cen-
tral event in neuronal apoptosis (reviewed in [2, 3]). The
role of JNK, mechanisms of its activation, and the sub-
sequent events leading to apoptosis have been particu-
larly well elucidated in sympathetic neurons withdrawn
from nerve growth factor (NGF). NGF withdrawal results
in the activation of small GTPases, such as Rac1 [4], and
the subsequent activation of a JNK signaling module
that ultimately results in phosphorylation of transcrip-
tion factors that include c-Jun [5–9]. The phosphory-
lated transcription factors function, in part, to facilitate
production of BH3 domain-only proteins, which are
proapoptotic members of the Bcl-2 family [10–12]. In-
duction of BH3 domain-only proteins leads to the re-
lease of mitochondrial contents and thereby initiates
the intrinsic apoptotic cascade.
The p75 neurotrophin receptor (p75NTR) and its
downstream interacting partner, NRAGE, can initiate
signaling events leading to neuronal apoptosis (re-
viewed in [13]). Work by ourselves and others have es-
tablished that, in both primary neurons and PC12 cells,
p75NTR- and NRAGE-induced cell death occurs
through induction of the JNK pathway, BH3 domain-
only protein activation, and release of mitochondrial
contents [14–16].
Because of the central role of JNK in neuronal cell
death, considerable attention has been focused on de-
veloping strategies to attenuate JNK signaling. One
widely pursued strategy is to develop chemical inhibi-
tors of JNK activity. Several kinase inhibitors that target
elements of the JNK activation pathway have emerged
[17, 18], and some of these compounds function as anti-
apoptotic compounds within in vitro and in vivo models
[19, 20]. Another approach is to identify endogenous in-
hibitors of JNKs that attenuate JNK pathway signaling.
Several proteins that directly modulate JNK signaling
have been identified [21–25], and the best characterized
of these is heat shock protein 70 (HSP70). HSP70 ex-
pression is often induced in cells exposed to stressful
stimuli, and its role in reducing stress-induced damage
through its chaperone function is well established [26].
Independent of its chaperone function, HSP70 can di-
rectly bind and inhibit JNK and thereby reduce apopto-
sis induced by a variety of insults [27–31]. It is conceiv-
able, therefore, that induction of HSP70 production
would provide an effective means of blocking apoptotic
JNK signaling.
In the present study, a search for novel compounds
that block JNK-induced cell death was conducted.
Screening for small-molecule inhibitors of sympathetic
neuron apoptosis induced by nerve growth factor
(NGF) withdrawal led to the identification of a novel com-
pound, AEG3482. AEG3482 blocked p75NTR- and
NRAGE-induced apoptosis of the PC12 neuronal
cell line and attenuated apoptotic JNK signaling. The
suppression of JNK signaling and apoptosis by
AEG3482 was mediated through induced HSP70
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way. Loss-of-function experiments, in which HSP70
levels were reduced by RNAi knockdown, confirmed
that HSP70 accumulation was required for AEG3482-
mediated suppression of JNK signaling. Collectively,
these studies demonstrate that AEG3482 is a potent
antiapoptotic compound that blocks the JNK signaling
pathway through increased expression of HSP70.
Results
The Synthetic Compound AEG3482 Inhibits NGF
Withdrawal-Induced Death in SCG Neurons
Survival of neonatal primary sympathetic neurons is de-
pendent on trophic support provided by NGF (reviewed
in [26]). To identify novel pharmacological inhibitors
of neuronal apoptosis, a high-throughput screen was
developed to identify compounds that block NGF with-
drawal-mediated death of primary sympathetic neu-
rons. Over 17,000 natural, synthetic, and semisynthetic
compounds were analyzed for their ability to inhibit
NGF withdrawal-induced apoptosis. One of the most
promising compounds to emerge from this screen was
an imidazothiadiazole sulfonamide of 281 D, which
was designated AEG3482 (Figure 1A). Survival of sym-
pathetic neurons withdrawn from NGF was strongly
enhanced in the presence of AEG3482, with an EC50 of
w20 mM (Figure 1B).
AEG3482 Inhibits p75NTR- or NRAGE-Induced
Apoptosis of PC12 Cells
We have previously shown that adenoviral-mediated
overexpression of p75NTR, or its cytosolic interactor,
NRAGE, leads to extensive JNK-dependent apoptosis
of PC12 cells and primary cortical neurons [14–16]. Be-
cause the signaling pathways that lead to p75NTR- or
NRAGE-induced cell death have been unambiguously
established in PC12 cells, this system was employed
to determine the mechanism of action of AEG3482. We
previously produced an adenovirus that drives NRAGE
expression via a doxycycline-inducible element (consti-
tutive NRAGE expression is cytotoxic; see [16] for de-
tails), and, for the experiments described below, a
PC12 subline (PC12rtTA) that stably expresses the doxy-
cycline-activated transcription factor, rtTA, was used.
PC12rtTA cells were infected with adenoviruses en-
coding p75NTR (Adp75), NRAGE (AdNRG), or, as a con-
trol, LacZ (AdLacZ), and they were concurrently
exposed to increasing concentrations of AEG3482 for
a period of 40 hr. Cell death was assessed by using
an LDH release assay. Overexpression of NRAGE or
p75NTR led to extensive death of PC12tTA cells, which
was strongly attenuated by cotreatment with AEG3482
in a dose-dependent manner (Figures 2A and 2B). Treat-
ment with 40 mM AEG3482 reduced p75NTR- or NRAGE-
induced cell death by greater than 90%. At the highest
concentration tested (80 mM), the compound effectively
inhibited apoptosis, but it also exerted a slight toxic ef-
fect in cells infected with the LacZ control. These results
indicated that the PC12tTA overexpression paradigm
provided a convenient and biochemically tractable sys-
tem for analyzing the mechanism of action of AEG3482.AEG3482 Inhibits p75NTR- or NRAGE-Mediated
JNK Activation
Activation of JNK is necessary for the induction of
p75NTR- or NRAGE-initiated caspase cleavage and
cell death [14, 16]. Therefore, the effect of AEG3482 on
the activity of JNK was assessed by analyzing alter-
ations in the phosphorylation level of the JNK target,
c-Jun, and the cleavage status of caspase-3. Fig-
ure 2C shows immunoblots of lysates of PC12rtTA cells
that were infected with AdNRG, or the control virus,
AdLacZ, in the presence of increasing concentrations
of AEG3482. In the absence of the compound, NRAGE
expression resulted in robust c-Jun phosphorylation
and caspase-3 cleavage. Levels of c-Jun protein were
also increased, presumably due to the auto-activation
of c-Jun transcription by phosphorylated c-Jun protein
[32]. Treatment with AEG3482 strongly attenuated
each of these effects; a significant decrease in c-Jun
phosphorylation and caspase-3 cleavage was detect-
able at 10 mM AEG3482 and was virtually complete at
40 mM. Figure 2D shows that similar results were ob-
tained in cells infected with Adp75 and treated with in-
creasing concentrations of AEG3482. Thus, the sup-
pression of JNK signaling and caspase-3 cleavage
mediated by AEG3482 occurred with a dose depen-
dency similar to the antiapoptotic activity of AEG3482.
Figure 1. The Synthetic Compound AEG3482 Inhibits NGF With-
drawal-Induced Cell Death
(A) Molecular structure of AEG3482 and its analogs. The compound
AEG3482 was isolated in a high-throughput screen for novel inhib-
itors of NGF withdrawal-induced death of sympathetic neurons.
Substitutions for position R1 are shown at the left.
(B) AEG3482 inhibits NGF withdrawal-induced death of SCG neu-
rons. Cultures of rat SCG neurons (see Experimental Procedures)
initially maintained in 10 ng/ml NGF were withdrawn from NGF
and maintained in media containing AEG3482 at the concentrations
indicated. After 2 days in AEG3482, cell viability was assayed by
using an MTS assay. (*p < 0.01 relative to no AEG3482). Results
are normalized to survival in 10 ng/ml NGF and represent the
mean +/2 standard deviation of an experiment performed in tripli-
cate (*p < 0.01 relative to no AEG3482).
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(A and B) AEG3482 inhibits (A) NRAGE- or (B) p75NTR-mediated cell death. PC12rtTA cells were infected with recombinant adenoviruses
expressing full-length NRAGE (AdNRG) at 5 multiplicity of infection (MOI), full-length p75NTR (Adp75) at 50 or 100 MOI, or the control protein
b-galactosidase (AdLacZ) at 5 MOI in (A) and 50 MOI in (B). At the time of infection, the cells were treated with an increasing concentration of
AEG3482 or with vehicle alone, as indicated. After 40 hr, cells were assayed for death by using the lactate dehydrogenase (LDH) assay; un-
treated cells (Un) and cells treated with 1% Triton X-100 (Tx) were used to delineate the output range of the assay. Results are normalized
relative to those obtained with 1% Triton X-100 and represent the mean 6 standard deviation of a representative experiment performed in
triplicate (*p < 0.005 relative to no AEG3482).
(C and D) AEG3482 inhibits NRAGE- and p75NTR-induced JNK activation. PC12rtTA cells were infected with (C) AdNRG at 5 MOI, with (D)
Adp75 at 50 MOI, or with AdLacZ at an equivalent MOI for each experiment, as indicated. At the time of infection, the cells were treated
with increasing concentrations of AEG3482 or with vehicle alone, as indicated. After 30 hr of infection, cells were lysed, normalized for protein
content, and analyzed for levels of phospho-Jun, total c-Jun, cleaved caspase-3, JNK, IkBa, (C) NRAGE, and (D) p75NTR, by immunoblotting.
(E) Cells were infected with AdNRG at 5 MOI or treated with paclitaxel, cisplatin, or doxorubicin (Dox) at the indicated micromolar concentra-
tions. At the time of treatment, AEG3482 or vehicle was added to the cultures, as indicated. After 40 hr, cells were assayed for death by using
the LDH assay. Results are normalized relative to those obtained with 1% Triton X-100 (Tx) and represent the mean 6 standard deviation of
a representative experiment performed in triplicate (*p < 0.01 relative to 0 mM AEG3482 for each insult).
Experiments in (A)–(D) were performed three times, and that in (E) was performed twice, with essentially identical results.
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by Paclitaxel and Cisplatin
The ability of AEG3482 to inhibit apoptosis in response
to a variety of other insults, including the DNA damaging
agent cisplatin, the microtubule disruptor paclitaxel,
and doxorubicin, a topoisomerase inhibitor, was investi-
gated. Previous studies demonstrate that cell death in-
duced by paclitaxel is dependent on JNK activation
[33–35], and Figure 2E shows that apoptosis induced
by low (10 mM) and high (50 mM) concentrations of pac-
litaxel is effectively reduced by AEG3482. Cisplatin-
induced apoptosis has been reported to be JNK depen-
dent when used at low concentrations (10 mM), but it
is JNK independent at concentrations >25 mM [36]; con-
sistent with this, AEG3482 protected cells exposed to
10 mM, but not 50 mM, cisplatin (Figure 2E). Doxorubicin-
induced apoptosis is JNK independent [35], and
AEG3482 treatment did not offer any protection against
doxorubicin-induced cell death. Collectively, these re-
sults are consistent with the hypothesis that AEG3482
inhibits apoptosis by blocking the JNK pathway.
AEG3482 Treatment Induces Expression of HSP70
The structure of AEG3482 does not resemble previously
identified kinase inhibitors, and AEG3482 has no effect
on JNK activity in vitro (data not shown). The conclusion
that AEG3482 does not directly suppress JNK activity
was supported by the observation that the JNK inhibi-
tory effects of AEG3482 occurred in cells subjected
to extended (i.e., 24 hr), but not short-term (i.e., 1 hr),
incubation with the compound (Figure 3A). These results
suggested that AEG3482 suppresses apoptotic sig-
naling through alternate means, possibly by enhanc-
ing transcription and translation of an endogenous fac-
tor that inhibits JNK activity. Several studies have
established that heat shock protein 70 (HSP70) can
bind and inhibit JNK [27–31], and the possibility that
AEG3482 promotes HSP70 production and thereby in-
hibits the JNK signaling pathway was therefore ex-
plored.
To address this, uninfected PC12rtTA cells were ex-
posed to AEG3482 for 18 hr, then lysed and assessed
for HSP70 levels by immunoblot. Figure 3B shows that
AEG3482 treatment does indeed result in a large in-
crease in cellular HSP70 levels. To test if the accumula-
tion of HSP70 induced by AEG3482 reflected increased
steady-state levels of its mRNA, RNA isolated from
PC12 cells treated with increasing concentrations of
AEG3482 for 18 hr was subjected to semiquantitative
rtPCR. Figure 3C shows that AEG3482 treatment in-
creased levels of HSP25 and HSP70 mRNA, but had
no effect on HSP90 or actin mRNA levels. HSP protein
levels were also assessed in PC12rtTA cells infected
with either AdLacZ, Adp75, or AdNRG and, at the
same time, exposed to AEG3482. Figure 3D shows
that treatment of PC12rtTA cells with increasing concen-
trations of AEG3482 resulted in a robust increase in
HSP70 and HSP25, but not HSP40, in cells infected
with either LacZ or with Adp75. Cells infected with
AdNRG showed enhanced expression of HSP70 even
in the absence of AEG3482. However, treatment of cells
infected with AdNRG pushed HSP70 levels substantially
higher that those observed with AdNRG alone.Transcriptional Regulation of HSP70 and HSP25,
but Not HSP40, Is Mediated by the Heat Shock
Factor 1 Transcription Factor
In unstimulated cells, HSF1 is maintained in an inactive,
latent state through an interaction with its binding part-
ner, HSP90. Induction of cell stress results in the interac-
tion of HSP90 with misfolded proteins and disrupts its
association with HSF1, allowing it to bind and activate
HSP70 and HSP25 promoters [36]. The specific effect
of AEG3482 on HSP25 and HSP70 production led us to
hypothesize that AEG3482 binds HSP90, causing it to
release HSF1, which then binds and activates HSP70
and HSP25 promoters. In initial experiments, the activity
of HSP70 transcriptional reporter constructs trans-
fected into PC12 cells was found to be stimulated by
AEG3482 (data not shown). To specifically address
whether HSF1 plays a role in this response, the effects
of AEG3482 on mouse embryonic fibroblasts (MEFs) de-
rived from either wild-type or HSF1 null mice were exam-
ined [37]. Figure 4A shows that transcriptional activity of
the HSP70 promoter reporter construct was strongly in-
duced by AEG3482 in wild-type MEFs, but that it re-
mained at baseline in MEFs lacking HSF1. Expression
of endogenous HSP proteins showed corresponding
changes in the MEFs, with strong induction of HSP70
and HSP25 in the wild-type cells, but not in MEFs lacking
HSF1 (Figure 4B).
These data indicate that AEG3482 mediates the pro-
duction of heat shock proteins through an HSF1-depen-
dent pathway, and they are consistent with the hypoth-
esis that AEG3482 directly binds HSP90. To test this
directly, AEG3482 was chemically crosslinked to Se-
pharose beads and used as an affinity reagent in pull-
down experiments. Beads were incubated with purified
HSP90 and washed extensively, and bound proteins
were then eluted and analyzed by SDS-PAGE and immu-
noblotting. Figure 4C shows that AEG3482 beads, but
not control beads, bound HSP90, and that this interac-
tion was strongly attenuated by incubation with excess
unbound AEG3482. Collectively, these data indicate
that AEG3482 directly binds HSP90, thereby facilitating
HSF1-dependent expression of HSP70 and HSP25.
AEG3482 Inhibition of JNK Activity Is Mediated
by the Induction of HSP70
Previous studies have shown that HSP70, but not
HSP25, is capable of blocking JNK activation [27–31],
and we therefore focused on the functional interaction
between AEG3482, HSP70 induction, and JNK pathway
inhibition. We first compared the cellular effects of three
analogs of AEG3482, which differed from the parental
compound in a single functional group (Figure 1). One
of these compounds (AEG19940) induced HSP70 pro-
duction, whereas two others (AEG33691 and AEG33733)
did not (Figure 5A). Compounds that induced HSP70
production (AEG3482 and AEG19940) were effective in
preventing Adp75- or AdNRG-induced cell death (Fig-
ure 5B) and reduced Jun phosphorylation (Figure 5C),
whereas the other compounds had no effect in these as-
say. Thus, by using these four related compounds,
a strong correlation emerged between the induction of
HSP70, the inhibition of JNK activity, and cell death.
Loss-of-function experiments were then used to es-
tablish a direct causal link between the induction of
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pression of HSP70
(A) PC12 cells were infected with 5 MOI
AdNRG (NRG) or AdLacZ (LacZ), as indi-
cated. Cells were left untreated (0), or they
were treated with 40 mM AEG3482 at the
time of infection (30), 1 hr before lysis (1),
or at both times (30 + 1). Cells were lysed
30 hr after infection, normalized for protein
content, and analyzed for levels of phos-
pho-Ser63 c-Jun and total c-Jun, total JNK,
IkBa, and NRAGE by immunoblotting.
(B) PC12 cells were treated with the indi-
cated concentrations of AEG3482 for 18 hr
and then lysed, normalized for protein con-
tent, and analyzed for levels of HSP70 by im-
munoblotting. Lysate from untreated cells is
indicated by ‘‘0.’’
(C) RNA isolated from PC12rtTA cells treated
with increasing concentrations of AEG3482
for 18 hr was analyzed by rtPCR with primers
specific to HSP70, HSP25, HSP90, or actin,
as indicated. RNA from untreated cells is in-
dicated by ‘‘0.’’ Experiments in (A) and (B)
were performed three times, and that in (C)
was performed twice, with essentially identi-
cal results.
(D) PC12rtTA cells were infected with AdNRG
at 5 MOI, Adp75 at 50 MOI, or the control vi-
rus AdLacZ at 50 MOI. At the time of infec-
tion, the cells were treated with increasing
concentrations of AEG3482 or with vehicle
alone, as indicated. After 30 hr of infection,
cells were lysed, normalized for protein con-
tent, and analyzed for levels of c-Jun phos-
phorylation, HSP70, HSP25, HSP40, NRAGE,
p75NTR, JNK-1, and IkBa, as indicated.HSP70 by these compounds and their JNK inhibitory ac-
tivity. For this, RNA interference directed against HSP70
was used to block its accumulation after treatment with
AEG3482. The expectation was that, if induction of
HSP70 by the compounds was required for JNK inhibi-
tion, then blocking the accumulation of HSP70 should
reduce the JNK inhibitory effect. Figure 6A shows that
transfection with HSP70 siRNA modestly attenuated ex-pression of HSP70 induced by AEG3482. The relatively
poor HSP70 knockdown likely reflects the low transfec-
tion efficiencies that can be achieved in PC12rtTA cells.
Despite this, a small, but consistent, attenuation in the
ability of AEG3482 to block c-Jun phosphorylation was
observed in cells transfected with HSP70 RNAi, consis-
tent with the hypothesis that HSP70 induction is re-
quired for this effect.
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Causes HSF1-Dependent Expression of
HSP70 and HSP25
(A) Wild-type or HSF1 null MEFs were trans-
fected with pGL3B-HSP70, an HSP70 pro-
moter reporter construct, or parental vector
(pGL3B), then treated with 40 mM AEG3482
for 24 hr and analyzed for luciferase content
as described in the Experimental Proce-
dures. Results represent the mean fold in-
crease over untreated wild-type MEFs trans-
fected with plasmid pGL3B +/2 standard
deviation of experiments performed in tripli-
cate (*p < 0.005 relative to no AEG3482;
**p < 0.005 relative to wild-type MEFs
treated with 40 mM AEG3482).
(B) Wild-type or HSF1 null MEFs were
treated with increasing concentrations of
AEG3482 for 24 hr, and cells were lysed, nor-
malized for protein content, and analyzed for
levels of HSP70, HSP40, and HSP25, as indi-
cated.
(C) AEG3482-conjugated Sepharose beads
were incubated with purified HSP90 for 2 hr
and washed, and levels of bound HSP90 were
analyzed by immunoblot. Con = control beads,
Alone = AEG3482 beads alone, Comp =
AEG3482 beads + competing AEG3482 (at
80 mM).
Experiments in (A)–(C) were performed three
times with identical results.To establish a firmer causal link between HSP70 in-
duction and JNK suppression, and to circumvent the
problem of low-transfection efficiency of the PC12rtTA
cells, a method was developed to assess JNK pathway
activation, specifically in the RNAi-transfected subpop-
ulation of PC12rtTA cells, by using a mammalian expres-
sion vector driving production of a fusion protein con-
taining GST fused to amino acids 2–79 of c-Jun. We
anticipated that the GST-c-Jun fusion protein would
be readily recoverable from lysates, and that its phos-
phostatus would provide a sensitive read-out that re-
flects the level of JNK pathway activation in the subpop-
ulation of cells that were transfected. Although overall
transfection efficiencies are low in PC12rtTA cells, the
GST-c-Jun fusion plasmid and the HSP70 siRNA would
be efficiently cotransfected, thereby providing an accu-
rate assessment of the effect of HSP70 depletion on JNK
signaling. To validate the GST-c-Jun fusion protein as an
in vivo reporter of JNK activity, PC12rtTA cells trans-
fected with GST-c-Jun were treated with TNF or ex-
posed to hyperosmotic shock, two stimuli commonly
used to activate the JNK signaling pathway [2]. GST-c-
Jun was then recovered from lysates, and its phosphos-
tatus was determined by immunoblotting. Figure 6B
shows that both TNF and hyperosmotic shock cause a
dramatic increase in phosphorylation of GST-jun which
is readily detected by immunoblot. Thus, the phosphos-
tatus of the GST-jun fusion protein provided a sensitive
read-out that reflects the level of JNK pathway activa-
tion in transfected cells.
We then asked if HSP70 accumulation was required to
block NRAGE-induced JNK activity. AEG3482 treatmentitself significantly increased expression of the GST-c-
Jun fusion construct, complicating the interpretation of
results (data not shown). As an alternative, AEG19940
was used since it robustly induced HSP70 production
(see Figure 5) without altering GST-jun expression
levels. Figure 6C shows that in cells transfected with
control siRNA, infection with AdNRG dramatically in-
creased phosphorylation of GST-c-Jun, whereas
AEG19940 strongly inhibited this effect. In cells trans-
fected with RNAi directed against HSP70, the ability of
AEG19940 to block GST-jun phosphorylation was al-
most completely lost, indicating that HSP70 accumula-
tion plays a crucial role in the JNK inhibition elicited by
this series of compounds.
AEG3482 and Geldanamycin Differ
in Their Mechanism of Action
Geldanamycin is a benzoquinone ansamycin that binds
to the ATP binding pocket of HSP90 (reviewed in [38–
40]. To determine if AEG3482 also occupies the HSP90
binding pocket, we compared AEG3482 and geldana-
mycin for their ability to block binding of HSP90 to
gATP-Sepharose. Figure 7A shows that purified HSP90
readily binds gATP-Sepharose, and that this binding is
strongly inhibited in the presence of free ATP. Geldana-
mycin also blocks association of HSP90 with gATP-
Sepharose, consistent with previous results [41]; in con-
trast, AEG3482 does not decrease the amount of HSP90
bound to gATP-Sepharose, but rather increased their
association.
By occupying the ATP binding pocket, geldanamycin
is thought to block the chaperone function of HSP90 and
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pression of HSP70
(A) PC12rtTA cells were infected with 5 MOI AdNRG, 50 MOI Adp75,
or 50 MOI of the control virus AdLacZ. At the time of infection, the
cells were treated with increasing concentrations of AEG3482; with
its analogs, AEG19940, AEG33691, and AEG33733; or with vehicle
alone, as indicated. After 30 hr of infection, cells were lysed, nor-
malized for protein levels, and analyzed for levels of HSP70,
HSP25, and JNK-1, as indicated.
(B) PC12rtTA cells were treated as described above, and after 40 hr
of infection, they were assayed for death by using the lactate dehy-
drogenase (LDH) assay. Results are normalized relative to those
obtained with 1% Triton X-100 and represent the mean 6 standard
deviation of a representative experiment performed in triplicate
(*p < 0.025 relative to 0 for each AEG concentration).
(C) PC12rtTA cells were infected with 50 MOI LacZ or 5 MOI AdNRG50,
and, at the time of infection, they were treated with 40 mM AEG3482;
with its analogs, AEG19940, AEG33691, and AEG33733; or with vehi-
cle alone, as indicated. After 30 hr of infection, cells were lysed, nor-
malized for protein levels, and were analyzed for phosphorylated
c-Jun, total c-Jun, NRAGE, and JNK-1, as indicated.
Experiments in (A)–(C) were performed twice, with essentially identi-
cal results.therefore reduce the stability and activity of HSP90
client proteins. We therefore compared the effects of
AEG3482 and geldanamycin on Akt, a pro-survival ki-
nase that is an HSP90 client protein. Figure 7B shows
that in PC12 cells, geldanamycin treatment lead to a dra-
matic reduction in levels of total and phosphorylated
Akt, consistent with previous results [42], whereas
AEG3482 significantly enhanced pAkt levels and re-
duced total Akt only slightly at the highest concentra-
tions tested.
Discussion
The present study indicates that the antiapoptotic activ-
ity of AEG3482 and its analogs arises from their ability to
block activation of the JNK pathway. Structurally,
AEG3482 does not resemble known kinase inhibitors,
and its time course of action suggested that it may func-
tion by facilitating production of an endogenous JNK
pathway antagonist. HSP70 is an endogenous inhibitor
of JNK activity [27–31], and our data show that
AEG3482 is a potent inducer of HSP70 production and
demonstrate that HSP70 accumulation is required for
the effect of AEG3482 on JNK signaling. To our knowl-
edge, this compound is the first shown to inhibit JNK ac-
tivation through a mechanism involving induced pro-
duction of HSP70.
HSPs are highly conserved proteins that are induced
by a wide variety of chemical and physiological stimuli
(reviewed in [43]). It is well established that HSPs play
crucial protective roles in stress responses, and that
they can suppress apoptosis induced by heat shock,
chemotherapeutic agents, nutrient withdrawal, ionizing
radiation, or TNF [43]. Induction of HSPs with sublethal
stresses gives rise to stress tolerance, and, in several
models, HSP70 has been identified as being the main
HSP responsible for resistance to future insults
[29, 44–47]. The protective nature of HSP70 and other
HSPs was originally attributed exclusively to their role
as molecular chaperones that prevented stress-induced
protein misfolding and aggregation and accelerated re-
folding [26]. However, recent findings have demon-
strated that, in addition to this function, HSP70 sup-
presses apoptosis by directly inhibiting components of
the JNK signaling pathway [27–31]. This inhibition in-
volves direct binding of HSP70 to JNK [28]. The precise
HSP70-JNK binding domains have not been identified,
but available data suggest that HSP70 binds JNK at, or
close to, the docking groove where interactions with
both JNK targets and activators occur. It is thus likely
that the HSP70-JNK association attenuates the interac-
tion of JNK with upstream MKKs and/or downstream
targets [28]. Inhibition of JNK by HSP70 does not appear
to be directly related to its chaperone function since
HSP70 mutants that lack chaperone function still inhibit
JNK; furthermore, HSP70 can inhibit JNK activation
even in the absence of stress-induced protein damage
[27, 28, 30].
Our data show that AEG3482 exposure results in the
accumulation of HSP25 and HSP70 mRNA and protein
in PC12 cells. Transcriptional regulation of these HSPs
normally requires the action of the HSF1 transcription fac-
tor, and we therefore asked if AEG3482 induces HSF1
activity. Transcriptional reporter assays demonstrated
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duced Expression of HSP70
(A) PC12rtTA cells were transfected with RNAi
directed against HSP70 or with control RNA,
then 24 hr later, they were infected with 5
MOI AdNRG or 50 MOI of the control virus
AdLacZ. At the time of infection, the cells
were treated with 40 mM AEG19940 or with
a vehicle control, as indicated. After 30 hr,
cells were lysed, normalized for protein
levels, and analyzed for phosphorylated
Jun, HSP70, HSP25, NRAGE, and actin
levels.
(B) PC12rtTA cells were transfected with an
expression construct driving GST-jun. After
24 hr, cells were infected with 5 MOI AdNRG
or 50 MOI of the control virus AdLacZ or
were left uninfected. After an additional
24 hr, uninfected cells were left untreated or
were exposed to 10 ng/ml TNF or 300 mM
sorbitol for 15 min. Cells were then lysed
and normalized for protein levels, and GST-
jun was recovered by glutathione pullout
and analyzed for phosphorylation by using
an antibody directed against c-Jun pSer63
by immunoblotting. Equivalent pullout of
GST-jun was confirmed by immunoblotting
with an antibody directed against c-Jun
and GST.
(C) PC12rtTA cells were cotransfected with an
expression construct driving GST-jun and
with RNAi directed against HSP70 or with
control RNA, as indicated. After 24 hr, cells
were infected with 5 MOI AdNRG or 50 MOI
of the control virus AdLacZ. At the time of in-
fection, the cells were treated with 40 mM
AEG19940 or with a vehicle control, as indi-
cated. After 30 hr, cells were lysed and nor-
malized for protein levels, and GST-jun was
recovered by glutathione pullout and ana-
lyzed for phosphorylation by using an anti-
body directed against c-Jun pSer63 by im-
munoblotting. Equivalent pullout of GST-jun
was confirmed by immunoblotting with an
antibody directed against total Jun. Lysate
levels of HSP70, HSP25, HSP40, NRAGE,
and actin were determined by immunoblot.
Experiments in (A) and (C) were performed
three times, and the experiment in (B) was
performed twice, all with essentially identical
results.that AEG3482 does indeed activate HSF1 transcriptional
activity, and comparison of wild-type MEFs with those
lacking HSF1 established that AEG3482 induces HSP25
and HSP70 production through an HSF1-dependent
pathway. HSF1 is normally maintained in a latent form
by virtue of its association with HSP90 [48], and we hy-
pothesized that an association of AEG3482 with HSP90
releases HSF1 and thereby facilitates HSP25 and
HSP70 transcription. Consistent with this, we found that
purified HSP90 directly binds AEG3482 in pullout assays.
HSP90 is composed of three main domains. The C-
terminal domain contains the HSP90 dimerization site
as well as docking sites for various cochaperones. The
central domain contains a large hydrophobic surface
that is involved in the binding of HSP90 client proteins,
and the N-terminal region contains the molecule’s
ATPase domain (reviewed in [40]). Unlike other chaper-
ones, most known client proteins of HSP90 are involvedin the regulation of survival and growth (reviewed in [38]).
Geldanamycin binds the ATP binding pocket of HSP90,
and this leads to allosteric changes in HSP90 that result
in release of HSF1 and subsequent expression of HSP25
and HSP70 [38–40, 48] Because this mechanism is sim-
ilar to that which we propose for AEG3482 and its ana-
logs, it is reasonable to expect that the cellular effects
of AEG3482 and geldanamycin treatment will be similar.
However, although scattered reports indicate that gel-
danamycin does confer protection to cells from pro-
tein-damaging stress in vitro and in vivo, the majority
of studies have shown that geldanamycin is cytotoxic
and kills a variety of normal and transformed cells, in-
cluding PC12 cells (reviewed in [38, 49]. The toxic effect
of geldanamycin is due to the fact that geldanamycin not
only releases bound HSF1, but, by occupying the ATP
binding pocket, blocks HSP90 chaperone activity and
reduces the stability and activity of HSP90 client
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221proteins that include Akt and Raf [42, 50–54]. There are
major structural and mechanistic differences between
geldanamycin and AEG3482, and it appears unlikely
that AEG3482 binds to the N-terminal ATP binding do-
main of HSP90, as does geldanamycin. We have shown
that AEG3482 does not occupy the ATP binding pocket
of HSP90 and demonstrated that, unlike geldanamycin,
AEG3482 does not reduce levels of Akt or block its
phosphorylation, but may instead enhance Akt phos-
phorylation. An enhancement of AKT and Raf activity
is observed during the misfolded protein response; mis-
folded proteins interact with the peptide binding do-
mains of HSP90 and cause the release of HSF1, and
our working hypothesis is that AEG3482 interacts with
a portion of the peptide binding domain of HSP90, and
that this facilitates HSF1 release while retaining HSP90
chaperone activity.
In conclusion, we have identified a class of com-
pounds that inhibit JNK activation by inducing produc-
tion of HSP proteins. We anticipate that AEG3482 and
its analogs will serve as useful tools for basic research,
and we believe that they have therapeutic potential for
the treatment of acute and chronic neurological disor-
ders.
Experimental Procedures
Materials
AEG3482, AEG19940, AEG33691, AEG33733, and AEG40011 were
produced at Aegera Therapeutics. Antibodies directed against
JNK1 and IkBa were purchased from Santa Cruz Biotechnology;
those against c-Jun, phospho-c-Jun, and cleaved caspase-3 were
Figure 7. AEG3482 and Geldanamycin Differ in Their Mechanism of
Action
(A) Purified HSP90 protein was preincubated with ATP, geldanamy-
cin (1 mM), or with the indicated concentrations of AEG3482 (indi-
cated in mM), and it was then mixed with gATP-Sepharose beads.
Bound HSP90 was eluted, and HSP90 content was determined
by immunoblotting.
(B) PC12 cells were exposed to increasing concentrations of
AEG3482 and geldanamycin (indicated in mM) for 16 hr, lysed,
and analyzed by immunoblotting for levels of phosphorylated and
total Akt, HSP70, HSP90, and actin, as indicated.purchased from Cell Signaling Technology; those against HSP25,
HSP40, and HSP70 were purchased from Stressgen; and that
against actin was purchased from ICN. Antibodies directed against
NRAGE and p75NTR have been previously described [16, 55]. The
PC12rtTA cell line was purchased from Clontech. HSP70-specific
small interfering RNAs consisted of a ‘‘SmartPool’’ mixture, which
was purchased from Dharmacon. Recombinant adenoviruses driv-
ing expression of b-galactosidase, p75NTR, and NRAGE have
been previously described [56]).
Cell Culture, Infection, Transfection, and Immunoblotting
Sympathetic neurons were maintained and deprived of NGF as pre-
viously described [57, 58]. PC12rtTA cells were maintained and in-
fected as previously described [16, 55]; for NRAGE, 1 mg/ml doxycy-
cline was added to all plates at the time of infection. Wild-type and
HSF1 nullizygous, immortalized mouse embryonic fibroblasts
(MEFs) were maintained in DMEM containing 10% fetal calf serum,
1 mM b-mercaptoethanol, 1% nonessential amino acids, 1% L-gluta-
mine, 1% antimycotic solution, and 1% sodium pyruvate (all from
GIBCO-BRL). Sympathetic neuron survival was assessed by using
the MTS assay according to the manufacturer’s instructions (Prom-
ega). Analysis of PC12 cell death was determined by using a lactate
dehydrogenase (LDH) assay (Roche) as per the manufacturer’s in-
structions. Transfections with plasmids or RNAi were performed
by using Lipofectamine 2000. Immunoblotting was performed as
previously described [16, 55].
Detection of Endogenous Phosphorylation of GST-c-Jun
The cDNA region corresponding to amino acids 2–79 of human
c-Jun was cloned into a mammalian GST expression vector [59],
and this was used to transfect PC12 cells. Lysates of transfected
cells were prepared and incubated with 20 ml glutathione-conju-
gated beads (Pharmacia) for 1 hr at 4ºC. Beads were washed three
times, resuspended in Lammeli sample buffer, and incubated at
100ºC for 5 min. The level of GST-c-Jun phosphorylation was as-
sessed by immunoblotting with a phospho-c-Jun-specific antibody.
RT-PCR
PC12 cells were treated with increasing concentrations of AEG3482
for 18 hr, and mRNA was isolated with RNEasy Mini kits (Qiagen).
cDNA was generated with the Omniscript RT kit (Qiagen) and ran-
dom hexamers (Roche) as primers. PCR was performed by using
primer pairs directed against rat HSP70, HSP25, and actin (primer
sequences and PCR conditions are available upon request).
Transcriptional Assays
MEFs were transfected with pGL3B-HSP70 or with the correspond-
ing parental vector. AEG3482 (40 mM) was added to the cells the next
day, and cells were harvested 48 hr after transfection. Transcrip-
tional assays were performed by using a luciferase assay system
purchased from Promega.
ATP-Sepharose Interaction Assays
These were performed essentially as described in [41]. Purified
HSP90 protein (1 mg) was preincubated with ATP, geldanamycin,
or AEG3482 in 200 ml incubation buffer (10 mM Tris [pH 7.5],
50 mM KCl, 5 mM MgCl2, 2 mM DTT, 20 mM Na2MoO4, and 0.01%
NP-40) for 10 min at room temperature. ATP-Sepharose beads
(25 ml) were added, and the reactions were incubated for 30 min at
30ºC. After thorough washing with Be ice-cold incubation buffer,
bound proteins were eluted in sample buffer, and HSP90 content
was determined by immunoblotting.
Statistical Analysis
For quantitation, each condition was performed in triplicate or qua-
druplicate, and results were analyzed by multiple analysis of vari-
ance with statistical probabilities assigned by using the Tukey test
for multiple comparisons.
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